Targeting RAS–ERK signalling in cancer: promises and challenges
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clinical outcome in metastatic melanoma and has shown promising clinical activity in additional tumour types. However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance. Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently associated with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of single agent therapies targeting individual RAS effector pathways is limited”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“combinations of inhibitors targeting multiple effector and/or feedback pathways have shown impressive activity in KRAS mutant model systems”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“Determinants of primary resistance are not the same in different tumor types that up-regulate various RTKs or their ligands in response to pathway inhibition (111-113).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [113]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Cited by
Items 601–700 of 1,000
Traditional Chinese herbal medicine: harnessing dendritic cells for anti-tumor benefits
Shen, M., Li, Z., Wang, J., Xiang, H., & Xie, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1408474 · Cited by 13
Elbeltagi, S., Al-Zharani, M. M., & Eldin, Z. E. (2025) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2025.113185 · Cited by 13
Urasaki, Y., Fiscus, R. R., & Le, T. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-28335-8 · Cited by 13
Liu, S., He, X., Man, V. H., Ji, B., Liu, J., & Wang, J. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp03803e · Cited by 13
Sayama, H., Marcantonio, D. H., Nagashima, T., Shimazaki, M., Minematsu, T., Apgar, J. F., Burke, J. M., Wille, L., Nagasaka, Y., & Kirouac, D. C. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12661 · Cited by 18
Chen, Y., Zang, H., Yang, C., Dong, L., Quan, S., Li, D., Li, Y., Dong, Q., Wang, F., & Li, L. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112234 · Cited by 13
Emerging Role of Noncoding RNAs in EGFR TKI-Resistant Lung Cancer
Li, J., Li, P., Shao, J., Liang, S., Wan, Y., Zhang, Q., Li, C., Li, Y., & Wang, C. (2022) · Cancers · doi:10.3390/cancers14184423 · Cited by 17
The Grb2 splice variant, Grb3-3, is a negative regulator of RAS activation
Seiler, C., Stainthorp, A. K., Ketchen, S., Jones, C. M., Marks, K., Quirke, P., & Ladbury, J. E. (2022) · Communications Biology · doi:10.1038/s42003-022-03985-7 · Cited by 16
Cheng, R., Lv, X., Bu, H., Xu, Q., Wu, J., Xie, K., Tang, J., Wang, L., Zhuang, J., Zhang, Y., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114808 · Cited by 16
Oxysterol-Binding Protein: new insights into lipid transport functions and human diseases
Lin, Y., Ran, L., Du, X., Yang, H., & Wu, Y. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2023.159365 · Cited by 15
Luo, S., Huang, G., Wang, Z., Wan, Z., Chen, H., Liao, D. K., Chen, C., Li, H., Li, B., Chen, L., et al. (2015) · PubMed Central · Cited by 13
Fan, Y., Weng, Z., Gao, H., Hu, J., Wang, H., Li, L., & Liu, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145790 · Cited by 13
BCL-2 proteins: melanoma lives on the edge
Chipuk, J. E. (2015) · Oncoscience · doi:10.18632/oncoscience.193 · Cited by 13
Goshen‐Lago, T., Goldberg-Carp, A., Kadosh, D. M., Darlyuk‐Saadon, I., Bai, C. G., Ahn, N. G., Admon, A., & Engelberg, D. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-03-0167 · Cited by 15
Ang, J. E., Pál, Á., Asad, Y. J., Henley, A. T., Valenti, M. R., Box, G., Brandon, A. D. H., Revell, V. L., Skene, D. J., Venturi, M., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0881 · Cited by 12
Sodium tungstate: Is it a safe option for a chronic disease setting, such as diabetes?
Bertinat, R., Westermeier, F., Gatica, R., & Nualart, F. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26913 · Cited by 13
Identification of lysine methylation in the core GTPase domain by GoMADScan
Yoshino, H., Yin, G., Kawaguchi, R. K., Popov, K. I., Temple, B. R. S., Sasaki, M., Kofuji, S., Wolfe, K., Kofuji, K., Okumura, K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219436 · Cited by 14
Medina, P. M. B., Ponce, J. M., & Cruz, C. A. K. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100940 · Cited by 13
Activity of New Synthetic (2-Chloroethylthio)-1,4-naphthoquinones in Prostate Cancer Cells
Dyshlovoy, S. A., Pelageev, D. N., Jakob, L. S., Borisova, K. L., Hauschild, J., Busenbender, T., Kaune, M., Khmelevskaya, E. A., Graefen, M., Bokemeyer, C., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14100949 · Cited by 13
Odeniyide, P., Shahab, S., Dunn, E. A., Rhee, D. S., Jiang, L., Dome, J. S., Friedman, A. D., Argani, P., & Pratilas, C. A. (2020) · Molecular Case Studies · doi:10.1101/mcs.a004820 · Cited by 14
Hershkovitz‐Rokah, O., Abeykoon, J. P., Ravindran, A., & Goyal, G. (2025) · Haematologica · doi:10.3324/haematol.2024.286479 · Cited by 13
ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination
Jones, J. K., Zhang, H., Lyne, A.-M., Cavalli, F. M. G., Hassen, W. E., Stevenson, K., Kornahrens, R., Yang, Y., Li, S., Dell, S., et al. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad095 · Cited by 13
Ye, J., Liu, W., Yu, X., Wu, L., Chen, Z., Yu, Y., Wang, J., Bai, S., & Zhang, M. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01675-9 · Cited by 12
Ku70 senses cytosolic DNA and assembles a tumor-suppressive signalosome
Pandey, A., Shen, C. X., Feng, S., Tuipulotu, D. E., Ngo, C., Liu, C., Kurera, M., Mathur, A., Venkataraman, S., Zhang, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adh3409 · Cited by 15
Alshabrmi, F. M., & Alatawi, E. A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132105 · Cited by 12
Li, Y.-T., Qian, X.-J., Yu, Y., Li, Z.-H., Wu, R.-Y., Ji, J., Jiao, L., Li, X., Kong, P., Chen, W.-D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3959 · Cited by 13
Lin, J.-X., Yoon, C., Li, P., Yu, Q., Qiu, S., Zheng, C., Yoon, S. S., & Huang, C. (2020) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-020-04616-4 · Cited by 15
Wang, W., Cui, X.-W., Gu, Y., Wei, C., Li, Y.-H., Ren, J.-Y., Chung, M., Aimaier, R., Zhang, H., Li, Q. F., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.07.164 · Cited by 15
Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Dong, Y., Gong, Y., Kuo, F., Makarov, V., Reznik, E., Nanjangud, G. J., Aras, Ö., Zhao, H., Qu, R., Fagin, J. A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0224 · Cited by 12
Wilmerding, A., Bouteille, L., Caruso, N., Bidaut, G., Etchevers, H., Graba, Y., & Delfini, M.-C. (2021) · Neoplasia · doi:10.1016/j.neo.2021.12.006 · Cited by 12
Hsa-miR-557 Inhibits Osteosarcoma Growth Through Targeting KRAS
Qiao, Z., Li, J., Kou, H., Chen, X., Bao, D., Shang, G., Chen, S., Ji, Y., Cheng, T., Wang, Y., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.789823 · Cited by 12
Qian, J., Li, Z., Pei, K., Li, Z., Li, C., Yan, M., Qian, M., Song, Y., Zhang, H., & He, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.712484 · Cited by 14
Liu, Y., Kang, L., Shi, S., Li, B., Zhang, Y., Zhang, X., Guo, X., Fu, G., Zheng, G., Hao, H., et al. (2022) · Neoplasma · doi:10.4149/neo_2022_211118n1640 · Cited by 12
Yang, S., Tang, Q., Chen, L., Chang, J., Jiang, T., Zhao, J., Wang, M., & Chen, P. R. (2020) · Angewandte Chemie · doi:10.1002/ange.202009572 · Cited by 12
Yin, W., Han, L., Li, P., Fu, X., & Huang, Z. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220615142636 · Cited by 12
Mai, A., Ye, S., Tu, J., Gao, J., Kang, Z., Yao, Q., & Ting, W. (2022) · Environmental Toxicology · doi:10.1002/tox.23664 · Cited by 14
Lu, L., Zhao, S., Gao, G., Sun, X.-H., Zhao, H., & Yang, H. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9772-y · Cited by 15
P-Rex1 is dispensable for Erk activation and mitogenesis in breast cancer
Barrio‐Real, L., López‐Haber, C., Casado‐Medrano, V., Goglia, A. G., Toettcher, J. E., Caloca, M. J., & Kazanietz, M. G. (2018) · Oncotarget · doi:10.18632/oncotarget.25584 · Cited by 13
Potential therapeutic targets for growth arrest of colorectal cancer cells exposed to PTHrP
Martín, M. J., Gigola, G., Zwenger, A. O., Carriquiriborde, M., Gentil, F., & Gentili, C. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.07.005 · Cited by 12
B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model
Köhler, M., Ehrenfeld, S., Halbach, S., Lauinger, M., Burk, U., Reischmann, N., Cheng, S., Spohr, C., Uhl, F. M., Köhler, N., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0663-8 · Cited by 13
Bulut, G., Atmaca, H., & Karaca, B. (2019) · Future Oncology · doi:10.2217/fon-2019-0521 · Cited by 12
Brown, C. N., Atwood, D. J., Pokhrel, D., Ravichandran, K., Holditch, S. J., Saxena, S., Miyazaki, M., Nemenoff, R. A., Weiser‐Evans, M. C. M., Ljubanović, D. G., et al. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109605 · Cited by 14
Hoang, V. T., Matossian, M. D., La, J., Hoang, K., Uçar, D. A., Elliott, S. G., Burks, H. E., Wright, T. D., Patel, S., Bhatt, A. B., et al. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29916 · Cited by 14
Erk phosphorylation reduces the thymoquinone toxicity in human hepatocarcinoma
Zhang, B., Ting, W., Gao, J., Kang, Z., Huang, C., & Weng, Y.-J. (2021) · Environmental Toxicology · doi:10.1002/tox.23317 · Cited by 12
Zeng, M., Li, Q., Chen, J., Huang, W.-F., Liu, J., Wang, C., Huang, M., Li, H., Zhou, S., Xie, M., et al. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.66929 · Cited by 11
Rack, S., Feeney, L., Hapuarachi, B. S., Adderley, H., Woodhouse, L. C., Betts, G. N. J., Burghel, G. J., Harrington, K. J., & Metcalf, R. L. (2022) · Cancers · doi:10.3390/cancers14051133 · Cited by 12
Hou, J., Chen, Q., Huang, Y., Wu, Z., & Ma, D. (2022) · Pharmaceutical Biology · doi:10.1080/13880209.2022.2050768 · Cited by 12
Minagawa, T., Yamazaki, K., Masugi, Y., Tsujikawa, H., Ojima, H., Hibi, T., Abe, Y., Yagi, H., Kitago, M., Shinoda, M., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13445 · Cited by 14
Xie, Q., Shen, Y., Meng, Y., Liang, J., Xu, J., Liang, S., Liu, X., Wang, Y., & Hu, C. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114579 · Cited by 11
Sustained ERK signaling promotes G2 cell cycle exit and primes cells for whole-genome duplication
Zuniga, A. G., Aikin, T. J., McKenney, C. D., Lendner, Y., Phung, A., Hook, P. W., Meltzer, A., Timp, W., & Regot, S. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.03.032 · Cited by 12
Predicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes
Cheng, G., Zhou, Z., Li, S., Yang, S., Wang, Y., Ye, Z., & Ren, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-61302-0 · Cited by 14
ERK Allosteric Activation: The Importance of Two Ordered Phosphorylation Events
Regev, C., Jang, H., & Nussinov, R. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169130 · Cited by 11
Insulin-IGF signaling affects cell transformation in the BALB/c 3T3 cell model
Poburski, D., Leovsky, C., Boerner, J. B., Szimmtenings, L., Ristow, M., Glei, M., & Thierbach, R. (2016) · Scientific Reports · doi:10.1038/srep37120 · Cited by 10
Gee, M. S., Ghazani, A. A., Haq, R., Wargo, J. A., Sebas, M., Sullivan, R. J., Lee, H., & Weissleder, R. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.12.006 · Cited by 11
Dai, C., Shen, L., Jin, W., Lv, B., Liu, P., Wang, X., Yin, Y., Fu, Y., Liang, L., Ma, Z., et al. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115273 · Cited by 11
Marini, E., Marino, M., Gionfriddo, G., Maione, F., Pandini, M., Oddo, D., Giorgis, M., Rolando, B., Blua, F., Gastaldi, S., et al. (2022) · Molecules · doi:10.3390/molecules27238513 · Cited by 12
Gao, R., Yang, K., Qu, Y., Wei, X., Shi, J., Lv, C., Zhao, Y., Sun, X., Xu, Y., & Yang, Y. (2023) · iScience · doi:10.1016/j.isci.2023.106215 · Cited by 12
Sekiya, S., Fukuda, J., Yamamura, R., Ooshio, T., Satoh, Y., Kosuge, S., Sato, R., Hatanaka, K. C., Hatanaka, Y., Mitsuhashi, T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3762 · Cited by 13
Guo, X., Yang, Y., He, W., & Wu, W. (2015) · Tumor Biology · doi:10.1007/s13277-015-3855-7 · Cited by 11
Holck, S., Nielsen, H. J., Pedersen, N., & Larsson, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5761 · Cited by 11
Gutiérrez-Malacatt, H., Ayala‐Sánchez, M., Aquino‐Ortega, X., Dominguez-Rodriguez, J., Martínez‐Tovar, A., Olarte-Carrillo, I., Martínez-Hernández, A. G., Contreras-Cubas, C., Orozco, L., & Córdova, E. J. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.4.2265 · Cited by 11
Starska, K., Forma, E., Jóźwiak, P., Lewy‐Trenda, I., Danilewicz, M., Stasikowska‐Kanicka, O., Skóra, M., Kolary-Siekierska, K., Miazga, J., Krześlak, A., et al. (2016) · Tumor Biology · doi:10.1007/s13277-016-5178-8 · Cited by 11
Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent Probe
Sipthorp, J., Lebraud, H., Gilley, R., Kidger, A. M., Okkenhaug, H., Saba-El-Leil, M. K., Meloche, S., Caunt, C. J., Cook, S. J., & Heightman, T. D. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00152 · Cited by 11
Imajo, M., Kondoh, K., Yamamoto, T., Nakayama, K., Nakajima‐Koyama, M., & Nishida, E. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00012-17 · Cited by 12
Limitations of molecularly targeted therapy
Balik, K., Modrakowska, P., Maj, M., Kaźmierski, Ł., & Bajek, A. (2019) · Medical Research Journal · doi:10.5603/mrj.a2019.0016 · Cited by 11
Zeng, X., Liu, Q., Yang, Y., Jia, W., Li, S., He, D., & Ma, R. (2019) · Oncology Letters · doi:10.3892/ol.2019.10911 · Cited by 11
Cheng, Z., Li, X., Hou, S., Wu, Y., Sun, Y., & Liu, B. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2019.1672756 · Cited by 11
Chen, J., Dai, J., Kang, Z., Yang, T., Zhao, Q., Zheng, J., Zhang, X., Zhang, J., Xu, J., Sun, G., et al. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112060 · Cited by 12
Patel, H. V., Johnson, M., Brea, R. J., Rudd, A. K., & Devaraj, N. K. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00222 · Cited by 12
Lan, T., Xia, X., Dunmall, L. C., Miao, J., & Wang, Y. (2021) · Aging · doi:10.18632/aging.202934 · Cited by 14
Djuzenova, C. S., Fischer, T., Katzer, A., Sisario, D., Korsa, T., Steußloff, G., Sukhorukov, V. L., & Flentje, M. P. (2021) · BMC Cancer · doi:10.1186/s12885-021-08930-1 · Cited by 11
Kim, G. D. (2021) · Preventive Nutrition and Food Science · doi:10.3746/pnf.2021.26.4.445 · Cited by 11
Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers
Li, X., Feng, Y. C., Hou, Q., Fu, Y., & Luo, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137168 · Cited by 12
Gebauer, N., Biersack, H., Czerwinska, A.-C., Schemme, J., Hardel, T. T., Bernard, V., Rades, D., Lehnert, H., Luley, K. B., & Thorns, C. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1046863 · Cited by 11
Lee, J., Park, I., Park, G., Cho, K., Park, H.-S., & Min, D. (2016) · Chemical Communications · doi:10.1039/c6cc05834e · Cited by 11
Fernandes, M. S., Melo, S., Velho, S., Carneiro, P., Carneiro, F., & Seruca, R. (2016) · Oncotarget · doi:10.18632/oncotarget.11843 · Cited by 12
Shin, W., Lee, S.-K., Hwang, J.-H., Park, J.-C., Cho, Y.-H., Ro, E. J., Song, Y., Seo, H. R., & Choi, K.-Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0102-5 · Cited by 10
Gastrointestinal cancer: molecular pathogenesis and targeted therapy
Jin, Y., He, X., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00361-9 · Cited by 15
Proteomic Studies of the Mechanism of Cytotoxicity, Induced by Palytoxin on HaCaT Cells
Cheng, D., Deng, B., Tong, Q., Gao, S., Xiao, B., Zhu, M., Ren, Z., Wang, L., & Sun, M. (2022) · Toxins · doi:10.3390/toxins14040269 · Cited by 10
Zhang, Q., & Liu, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216691 · Cited by 11
Xu, C., Chen, G., Yu, B., Sun, B., Zhang, Y., Zhang, M., Yang, Y., Xiao, Y., Cheng, S., Li, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202400023 · Cited by 17
Wang, S. Q., Goh, S. S., Chai, C. L. L., & Chen, A. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob01948f · Cited by 10
Hoang, T. T., Tanrikulu, I. C., Vatland, Q. A., Hoang, T. M., & Raines, R. T. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0724 · Cited by 11
Ras Multimers on the Membrane: Many Ways for a Heart-to-Heart Conversation
Özdemir, E. S., Koester, A. M., & Nan, X. (2022) · Genes · doi:10.3390/genes13020219 · Cited by 11
Copper in Cancer: from transition metal to potential target
Fang, C., Peng, Z., Sang, Y., Ren, Z., Ding, H., Yuan, H., & Hu, K. (2023) · Human Cell · doi:10.1007/s13577-023-00985-5 · Cited by 11
Proteomic‐based investigations on the mode of action of the marine anticancer compound rhizochalinin
Dyshlovoy, S. A., Otte, K., Venz, S., Hauschild, J., Junker, H., Makarieva, T. N., Balabanov, S., Alsdorf, W. H., Madanchi, R., Honecker, F. U., et al. (2017) · PROTEOMICS · doi:10.1002/pmic.201700048 · Cited by 10
A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases
Miller, C. J., Muftuoglu, Y., & Turk, B. E. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.06.127 · Cited by 10
Kent, O. A., Sandí, M. J., & Rottapel, R. K. (2017) · Small GTPases · doi:10.1080/21541248.2017.1337545 · Cited by 11
RanBPM: a potential therapeutic target for modulating diverse physiological disorders
Das, S., Suresh, B., Kim, S., & Ramakrishna, S. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.08.005 · Cited by 11
Bai, G., Yang, M., Zheng, C., Zhang, L., & Eli, M. (2018) · Oncology Letters · doi:10.3892/ol.2018.8004 · Cited by 13
Wang, T., Wang, D., Zhang, Y., Zhang, J., Sun, X., Wu, Y., Wang, S., Zhang, Y., Xu, L., Kong, Q., et al. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.09.017 · Cited by 10
HOXB8 Counteracts MAPK/ERK Oncogenic Signaling in a Chicken Embryo Model of Neoplasia
Wilmerding, A., Bouteille, L., Rinaldi, L., Caruso, N., Graba, Y., & Delfini, M.-C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168911 · Cited by 10
Liu, L., Chen, Y., Lin, X., Wu, M., Li, J., Xie, Q., Sferra, T. J., Han, Y., Liu, H., Cao, L., et al. (2021) · PubMed Central · doi:10.1186/s12935-021-02246-7 · Cited by 10
Takao, T., Masuda, H., Kajitani, T., Miki, F., Miyazaki, K., Yoshimasa, Y., Katakura, S., Tomisato, S., Uchida, S., Uchida, H., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02888-y · Cited by 11
Tolypocladamides A–G: Cytotoxic Peptaibols from Tolypocladium inflatum
Senadeera, S. P. D., Wang, D., Kim, C., Smith, E. A., Durrant, D., Alexander, P., Wendt, K. L., Stephen, A. G., Morrison, D. K., Cichewicz, R. H., et al. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.2c00240 · Cited by 10
Atypical signaling of metabotropic glutamate receptor 1 in human melanoma cells
Gelb, T., Pshenichkin, S. P., Hathaway, H. A., Grajkowska, E., Dalley, C. B., Wolfe, B. B., & Wroblewski, J. T. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.091 · Cited by 10
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
Schiemann, W. P., Gollamudi, J., Parvani, J. G., & Vinayak, S. (2016) · Cancer Management and Research · doi:10.2147/cmar.s55279 · Cited by 12
Wei, X., Zhou, J., Hong, L., Xu, Z., Zhao, H., Wu, X., & Chen, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8900 · Cited by 11
Chang, Q., Long, J., Hu, L., Chen, Z., Li, Q., & Hu, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115404 · Cited by 10
Brioschi, M., Martínez, A. E., & Banfi, C. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1332998 · Cited by 11
Metadata
- Authors
- Samatar, A. A., & Poulikakos, P. I.
- Affiliations
- Tisch Cancer Institute (US)
- Corresponding author
- Poulikakos, Poulikos I.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-12
- Volume
- 13
- Issue
- 12
- Pages
- 928-942
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2050573392
- Cited by
- 1,163
- References
- 139
- Citations by year
- 2026: 47 · 2025: 77 · 2024: 106 · 2023: 100 · 2022: 102 · 2021: 134 · 2020: 119 · 2019: 105 · 2018: 117 · 2017: 101 · 2016: 108 · 2015: 45 · 2014: 2
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- RAF inhibitors, MEK inhibitors, ERK inhibitor, KRAS mutation, NRAS mutation, BRAF mutation, acquired drug resistance, intrinsic drug resistance, metastatic melanoma, targeted cancer therapy, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.